首药控股跌1.8% 2022年上市募15亿

Core Viewpoint - Shouyao Holdings (688197.SH) is currently experiencing a decline in stock price, closing at 36.53 yuan with a drop of 1.80%, indicating it is in a state of post-IPO underperformance [1] Group 1: Company Overview - Shouyao Holdings was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 23, 2022, with an initial offering price of 39.90 yuan per share [1] - The company issued a total of 37.18 million shares, which represents 25.00% of the total share capital after the issuance [1] Group 2: Fundraising and Financials - The total amount raised during the IPO was 1.483 billion yuan, with a net amount of 1.374 billion yuan after deducting issuance costs [1] - The company aimed to raise 2.0 billion yuan, which was intended for innovative drug research and development projects, the establishment of a new drug R&D and industrialization base, and to supplement working capital [1] - The total issuance costs amounted to 110 million yuan, with the lead underwriter, CITIC Securities, receiving 90.8957 million yuan in underwriting fees [1]